Blog

Yüksel Ürün: Did you know the FDA approved cancer drugs target fewer than 200 proteins?

Photo from Yüksel Ürün/X

Jul 1, 2024, 15:09

Yüksel Ürün: Did you know the FDA approved cancer drugs target fewer than 200 proteins?

Yüksel Ürün shared a post on X:

“Did you know the FDA approved cancer drugs target fewer than 200 proteins?

Integrating proteogenomics data from 1,043 patients identified new therapeutic targets.
Analysis of 2,863 druggable proteins revealed key mRNA-protein correlations.
Tumor proteomics and genetic screens uncovered druggable dependencies and synthetic lethality strategies.”

Source: Yüksel Ürün/X

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field. .

biomedical research cancer cancer drugs Cancer research Druggable Proteins FDA Genetic Screens OncoDaily Oncology Precision Medicine proteogenomics Synthetic Lethality therapeutic targets Tumor Proteomics

FDA approval: Pembrolizumab for HER2 positive gastric or GEJ adenocarcinoma expressing PD-L1 (CPS ≥1): KEYNOTE-811 Trial

Changing the Future of Adolescent and Young Adult Cancer Care

OncoDaily Launches New Social Channel on Telegram – @OncoDaily

In Memory of Chadwick Boseman and His Colon Cancer Battle

Groundbreaking Canadian Cancer Society-funded research aims to reshape the future of advanced cancer